CAR-T cell therapy for hematological malignancies: History, status and promise

Chao Wang; Jianpeng Wang; Shusheng Che; Hai Zhao

doi:10.1016/j.heliyon.2023.e21776

CAR-T cell therapy for hematological malignancies: History, status and promise

Heliyon. 2023 Nov 7;9(11):e21776. doi: 10.1016/j.heliyon.2023.e21776. eCollection 2023 Nov.

Authors

Chao Wang¹, Jianpeng Wang¹, Shusheng Che¹, Hai Zhao¹

Affiliation

¹ Department of Neurosurgery, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, China.

Abstract

For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) uses the patient's own T cells to express chimeric antigen receptors. Chimeric antigen receptor (CAR) recognizes tumor-associated antigens and kills tumor cells. CAR-T has achieved good results in the treatment of hematological tumors. In 2017, the FDA approved the first CAR-T for the treatment of B-cell acute lymphoblastic leukemia (ALL). In October of the same year, the FDA approved CAR-T to treat B-cell lymphoma. In order to improve and enhance the therapeutic effect, CAR-T has become a research focus in recent years. The structure of CAR, the targets of CAR-T treatment, adverse reactions and improvement measures during the treatment process are summarized. This review is an attempt to highlight recent and possibly forgotten findings of advances in chimeric antigen receptor T cell for treatment of hematological tumors.

Keywords: Chimeric antigen receptor; Hematological malignancies; T cell immunotherapy; Target therapy.

Publication types

Review